

## 产品名称: YYA-021

产品别名: YYA-021

### 生物活性:

<b>Description</b>	YYA-021 is a small-molecule CD4 mimic that inhibits HIV entry, with high anti-HIV activity and low cytotoxicity. IC50 value: 8.4 $\mu$ M Target: HIV IC50 (=8.4 $\mu$ M) value of YYA-021 is determined by a single round assay using cYTA48P virus and TZM-bl cells. YYA-021 is broadly distributed in tissues, probably as a result of its hydrophobicity. The plasma concentrations of YYA-021 in both species remained at micromolar levels for several hours post-injection. [1] YYA-021 also enhances the neutralizing activity of KD-247 against simian-human immunodeficiency virus (SHIV)-KS661 strain via highly synergistic interactions. YYA-021 might have promise as a lead compound for the intravenous administration in a cocktail therapy with anti-gp120 monoclonal antibodies such as KD-247 and with co-receptor antagonists such as T140. [2]																					
<b>Solvent&amp;Solubility</b>	<p><b>In Vitro:</b></p> <p>DMSO : 50 mg/mL (157.52 mM; Need ultrasonic)</p> <p>H<sub>2</sub>O : &lt; 0.1 mg/mL (insoluble)</p> <table border="1" data-bbox="446 871 1356 1073"><thead><tr><th rowspan="2"></th><th>Solvent Concentration</th><th>Mass</th><th>1 mg</th><th>5 mg</th><th>10 mg</th></tr></thead><tbody><tr><td>Preparing Stock Solutions</td><td>1 mM</td><td>3.1503 mL</td><td>15.7515 mL</td><td>31.5030 mL</td></tr><tr><td></td><td>5 mM</td><td>0.6301 mL</td><td>3.1503 mL</td><td>6.3006 mL</td></tr><tr><td></td><td>10 mM</td><td>0.3150 mL</td><td>1.5752 mL</td><td>3.1503 mL</td></tr></tbody></table> <p>*请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液。一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。</p> <p>储备液的保存方式和期限 -80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。</p> <p><b>In Vivo:</b></p> <p>请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 <b>In Vitro</b> 方式配制澄清的储备液，再依次添加助溶剂：</p> <p>——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶。</p> <p>1. 请依序添加每种溶剂： 10% DMSO → 40% PEG300 → 5% Tween-80 → 45% saline</p> <p>Solubility: ≥ 2.5 mg/mL (7.88 mM); Clear solution</p> <p>此方案可获得 ≥ 2.5 mg/mL (7.88 mM, 饱和度未知) 的澄清溶液。</p> <p>以 1 mL 工作液为例，取 100 <math>\mu</math>L 25.0 mg/mL 的澄清 DMSO 储备液加到 400 <math>\mu</math>L PEG300 中，混合均匀。向上述体系中加入 50 <math>\mu</math>L Tween-80，混合均匀；然后继续加入 450 <math>\mu</math>L 生理盐水定容至 1 mL。</p> <p>2. 请依序添加每种溶剂： 10% DMSO → 90% (20% SBE-β-CD in saline)</p> <p>Solubility: 2.5 mg/mL (7.88 mM); Suspended solution; Need ultrasonic</p> <p>此方案可获得 2.5 mg/mL (7.88 mM) 的均匀悬浊液，悬浊液可用于口服和腹腔注射。</p> <p>以 1 mL 工作液为例，取 100 <math>\mu</math>L 25.0 mg/mL 的澄清 DMSO 储备液加到 900 <math>\mu</math>L 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。</p> <p>3. 请依序添加每种溶剂： 10% DMSO → 90% corn oil</p>		Solvent Concentration	Mass	1 mg	5 mg	10 mg	Preparing Stock Solutions	1 mM	3.1503 mL	15.7515 mL	31.5030 mL		5 mM	0.6301 mL	3.1503 mL	6.3006 mL		10 mM	0.3150 mL	1.5752 mL	3.1503 mL
	Solvent Concentration		Mass	1 mg	5 mg	10 mg																
	Preparing Stock Solutions	1 mM	3.1503 mL	15.7515 mL	31.5030 mL																	
	5 mM	0.6301 mL	3.1503 mL	6.3006 mL																		
	10 mM	0.3150 mL	1.5752 mL	3.1503 mL																		

	<p>Solubility: <math>\geq 2.5 \text{ mg/mL}</math> (7.88 mM); Clear solution</p> <p>此方案可获得 <math>\geq 2.5 \text{ mg/mL}</math> (7.88 mM, 饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。</p> <p>以 1 mL 工作液为例，取 100 <math>\mu\text{L}</math> 25.0 mg/mL 的澄清 DMSO 储备液加到 900 <math>\mu\text{L}</math> 玉米油中，混合均匀。</p>
<b>References</b>	<p>[1]. <a href="#">Mizuguchi T, et al. A minimally cytotoxic CD4 mimic as an HIV entry inhibitor. Bioorg Med Chem Lett. 2016 Jan 15;26(2):397-400.</a></p> <p>[2]. <a href="#">Hashimoto C, et al. A CD4 mimic as an HIV entry inhibitor: pharmacokinetics. Bioorg Med Chem. 2013 Dec 15;21(24):7884-9.</a></p>



源叶生物